Project Grant R44AG097127
Award Date 9/20/25
Completion Date 5/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The National Institute on Aging (NIA), through its Aging Research Federal Grant Program (CFDA 93.866), awarded a $498,709 project grant to Epoch Biotech, LLC on August 20, 2025. The funding supports preclinical research on an ApoE-targeted antibody for treating Alzheimer's disease (AD). The project aims to modulate the interaction between apolipoprotein E (ApoE) and glycosaminoglycans (GAGs) using a therapeutic humanized antibody. The research builds on the discovery of a protective ApoE3...
- This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $9,781,240 Project Grant to the Institute For Molecular Medicine Inc. in California. The grant funds a multicenter Phase 1 clinical trial to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals at risk of Alzheimer's disease (preclinical stage). The project aims to develop an innovative immunotherapy approach for...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $412,500 Project Grant to the University of South Florida to investigate changes in the brain extracellular matrix during normal aging and in Alzheimer's disease. The 2-year grant, which runs from Jun 1, 2025 to May 31, 2027, aims to establish region-specific extracellular matrix composition in mouse brains, elucidate changes during normal aging, and characterize temporal and spatial...
- The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons...